145 related articles for article (PubMed ID: 37652775)
1. A case report of hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) for malignant peritoneal mesothelioma.
Liu H; Yuan C; Huang Y; Xu N
Asian J Surg; 2023 Dec; 46(12):5747-5748. PubMed ID: 37652775
[No Abstract] [Full Text] [Related]
2. ASO Author Reflections: Perioperative Systemic Chemotherapy in Diffuse Malignant Peritoneal Mesothelioma treated with CRS-HIPEC.
Chatterjee A; Kusamura S; Baratti D; Guaglio M; Battaglia L; Deraco M
Ann Surg Oncol; 2024 Apr; 31(4):2511-2512. PubMed ID: 38219000
[No Abstract] [Full Text] [Related]
3. ASO Author Reflections: International Standardization of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Protocols-Malignant Peritoneal Mesothelioma as a Model.
Kepenekian V; Sgarbura O; Marchal F; Villeneuve L; Kusamura S; Deraco M
Ann Surg Oncol; 2023 Nov; 30(12):7858-7859. PubMed ID: 37626249
[No Abstract] [Full Text] [Related]
4. Delayed CRS-HIPEC Is Associated with Decreased Survival in Patients with Malignant Peritoneal Mesothelioma: A Markov Decision Analysis.
Rouhi AD; Choudhury RA; Hoeltzel GD; Yule A; Williams NN; Dumon KR; Karakousis GC
J Gastrointest Surg; 2023 May; 27(5):995-997. PubMed ID: 36443555
[No Abstract] [Full Text] [Related]
5. Perioperative Systemic Chemotherapy in Patients with Malignant Peritoneal Mesothelioma Undergoing Cytoreduction and HIPEC: Don't Put the Cart Before the Horse.
Alexander HR
Ann Surg Oncol; 2023 Oct; 30(11):6301-6303. PubMed ID: 37358682
[No Abstract] [Full Text] [Related]
6. Ten-year single-center experience with treatment of primary diffuse malignant peritoneal mesothelioma (DMPM) by cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
Acs M; Gerken M; Gajic I; Mayr M; Zustin J; Piso P
Langenbecks Arch Surg; 2022 Nov; 407(7):3057-3067. PubMed ID: 35732846
[TBL] [Abstract][Full Text] [Related]
7. Cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma: Canadian practices and outcomes.
Deban M; Taqi K; Knapp GC; Soucisse M; Curry M; Sidéris L; Dubé P; Khaldi MA; Jedrzejko N; Porter G; Giacomantonio C; Hamilton T; MacNeill A; Mack L; Bouchard-Fortier A
J Surg Oncol; 2023 Sep; 128(4):595-603. PubMed ID: 37249154
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Survival in Patients Treated with Cytoreduction and Heated Intraperitoneal Chemotherapy for Peritoneal Mesothelioma at a Single High-Volume Center.
Valenzuela CD; Solsky IB; Erali RA; Forsythe SD; Mangieri CW; Mainali BB; Russell G; Perry KC; Votanopoulos KI; Shen P; Levine EA
Ann Surg Oncol; 2023 May; 30(5):2666-2675. PubMed ID: 36754945
[TBL] [Abstract][Full Text] [Related]
9. Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent or progressive diffuse malignant peritoneal mesothelioma: clinicopathologic characteristics and survival outcome.
Ihemelandu C; Bijelic L; Sugarbaker PH
Ann Surg Oncol; 2015 May; 22(5):1680-5. PubMed ID: 25120250
[TBL] [Abstract][Full Text] [Related]
10. Conversion to Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma After Bidirectional Chemotherapy.
Le Roy F; Gelli M; Hollebecque A; Honoré C; Boige V; Dartigues P; Benhaim L; Malka D; Ducreux M; Elias D; Goéré D
Ann Surg Oncol; 2017 Nov; 24(12):3640-3646. PubMed ID: 28849389
[TBL] [Abstract][Full Text] [Related]
11. Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for malignant peritoneal mesothelioma.
Klos D; Hanuliak J; Lemstrova R; Mohelnikova-Duchonova B; Zapletalova J; Melichar B; Risko J
Bratisl Lek Listy; 2023; 124(5):345-350. PubMed ID: 36876363
[TBL] [Abstract][Full Text] [Related]
12. Multicystic and diffuse malignant peritoneal mesothelioma in children.
Vermersch S; Arnaud A; Orbach D; Andre N; Berger C; Kepenekian V; Brigand C; Fresneau B; Poli-Merol ML; Habougit C; Varlet F; Scalabre A
Pediatr Blood Cancer; 2020 Jun; 67(6):e28286. PubMed ID: 32277799
[TBL] [Abstract][Full Text] [Related]
13. 2022 PSOGI Consensus on HIPEC Regimens for Peritoneal Malignancies: Diffuse Malignant Peritoneal Mesothelioma.
Kepenekian V; Sgarbura O; Marchal F; Villeneuve L; Kusamura S; Deraco M
Ann Surg Oncol; 2023 Nov; 30(12):7803-7813. PubMed ID: 37481492
[TBL] [Abstract][Full Text] [Related]
14. Establishment of a Bayesian network model to predict the survival of malignant peritoneal mesothelioma patients after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy.
Su YD; Zhao X; Ma R; Fu YB; Yang ZR; Wu HL; Yu Y; Yang R; Liang XL; Du XM; Chen Y; Li Y
Int J Hyperthermia; 2023; 40(1):2223374. PubMed ID: 37348853
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial.
de Boer NL; van Kooten JP; Burger JWA; Verhoef C; Aerts JGJV; Madsen EVE
BMJ Open; 2019 May; 9(5):e026779. PubMed ID: 31092657
[TBL] [Abstract][Full Text] [Related]
16. Impact of Perioperative Systemic Chemotherapy on Survival for Patients Who have Diffuse Malignant Peritoneal Mesothelioma Treated with CRS-HIPEC.
Chatterjee A; Kusamura S; Baratti D; Guaglio M; Battaglia L; Deraco M
Ann Surg Oncol; 2024 Jan; 31(1):556-566. PubMed ID: 37940804
[TBL] [Abstract][Full Text] [Related]
17. The Role of Ki-67 and Pre-cytoreduction Parameters in Selecting Diffuse Malignant Peritoneal Mesothelioma (DMPM) Patients for Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Kusamura S; Torres Mesa PA; Cabras A; Baratti D; Deraco M
Ann Surg Oncol; 2016 May; 23(5):1468-73. PubMed ID: 26572754
[TBL] [Abstract][Full Text] [Related]
18. Treating peritoneal mesothelioma with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. A case series and review of the literature.
Stamou K; Tsamis D; Pallas N; Samanta E; Courcoutsakis N; Prassopoulos P; Tentes AA
Int J Hyperthermia; 2015; 31(8):850-6. PubMed ID: 26382910
[TBL] [Abstract][Full Text] [Related]
19. Early recurrence after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
Tan GHC; Chia CS; Tan SH; Soo KC; Teo MCC
Int J Clin Oncol; 2018 Oct; 23(5):989-998. PubMed ID: 29869757
[TBL] [Abstract][Full Text] [Related]
20. A comprehensive review of childbearing after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Papageorgiou D; Manatakis DK; Papakonstantinou K; Kyriazanos ID
Arch Gynecol Obstet; 2020 Oct; 302(4):793-799. PubMed ID: 32653946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
